Vkavka Wart Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the effective removal of both common warts and plantar warts. Common warts are characterized by their raised, rough texture, which resembles the surface of a cauliflower. Plantar warts occur specifically on weight-bearing areas of the foot and are typically associated with pressure pain during ambulation, as well as noticeable disruption of the natural skin ridge patterns of the foot.

Limitations of Use: This drug is not indicated for the treatment of warts located on the face, genitals, or mucous membranes.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. It is recommended to soak the wart in warm water for approximately 5 minutes to facilitate the removal process. After soaking, the area must be dried completely.

A sufficient amount of the medication should be applied using a brush to ensure complete coverage of each wart. It is important to allow the medication to fully absorb and dry on the skin.

This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application is not recommended on irritated skin or any area that is infected or reddened, as this may exacerbate the condition. The product should not be applied to moles, birthmarks, warts with hair growing from them, or warts located on the face or mucous membranes due to the potential for adverse reactions. Additionally, individuals with a known hypersensitivity disorder, diabetes mellitus, or poor blood circulation should avoid use, as these conditions may increase the risk of complications.

Warnings and Precautions

Use of this product is restricted to application on the skin surface only. It is imperative to avoid exposure to fire and flame during use. Precise application is crucial; the product should be applied exclusively to the wart, ensuring that surrounding skin remains uncovered.

General precautions must be observed to ensure safe use. The product should not be applied to irritated skin or any area that appears infected or reddened. Additionally, it is contraindicated for use on moles, birthmarks, warts with hair growth, warts located on the face, or on mucous membranes. Individuals with known hypersensitivity disorders, diabetes mellitus, or poor blood circulation should refrain from using this product.

Patients are advised to discontinue use and consult a healthcare professional if discomfort persists. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Side Effects

Patients should be advised to use the product exclusively on the skin surface and to avoid contact with fire and flame. It is essential to apply the product precisely, covering only the wart and avoiding the surrounding skin to minimize the risk of adverse reactions.

In the event that discomfort persists, patients are instructed to discontinue use of the product. This precaution is critical to ensure patient safety and to prevent potential complications associated with continued application.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Vkavka Wart Remover (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

There is no specific information regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. The potential risks and benefits should be carefully evaluated, and alternative treatments may be considered in consultation with the patient. Women of childbearing potential should be advised to discuss their pregnancy status and any plans for pregnancy with their healthcare provider prior to initiating treatment.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects during lactation. Consequently, healthcare professionals should exercise caution when considering this medication for lactating mothers. The potential risks and benefits should be carefully evaluated, and alternative treatments may be considered if necessary. Breastfed infants may be affected by medications taken by their nursing mothers; therefore, monitoring for any adverse effects is advisable.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data regarding its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters have not been defined.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Monitoring of vital signs and laboratory parameters may be warranted to assess the patient's condition and guide further management.

Healthcare professionals should remain vigilant for potential symptoms that could indicate an overdosage scenario, although specific symptoms have not been detailed. If any adverse reactions or unexpected clinical presentations occur, appropriate medical intervention should be sought immediately.

For further guidance, healthcare providers are encouraged to consult local poison control centers or relevant medical authorities to obtain the most current recommendations for managing suspected overdosage cases.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children. Instruct patients that if the product is swallowed, they should seek medical help or contact the Poison Control Center at 1-800-222-1222 immediately.

Patients should be informed to avoid contact with the eyes. If the product accidentally gets into the eye, they should flush the eye with water for at least 15 minutes and seek medical attention if irritation persists.

It is important to counsel patients to avoid inhaling vapors from the product. Additionally, they should be reminded to cap the product tightly after use and store it at room temperature, away from heat sources.

Finally, healthcare providers should emphasize that the product is non-edible and should not be ingested.

Storage and Handling

The product is supplied in a tightly capped container. It should be stored at room temperature, ensuring it is kept away from heat sources to maintain its integrity and efficacy.

Additional Clinical Information

The product is administered topically, with the recommended frequency of application being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. Clinicians should counsel patients to avoid contact with the eyes; in the event of exposure, the eye should be flushed with water for 15 minutes. Patients are also advised to avoid inhaling vapors and to keep the product out of reach of children. If ingested, immediate medical assistance should be sought or the Poison Control Center (1-800-222-1222) should be contacted.

No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Vkavka Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)